There is growing scientific evidence that fenbendazole, as well as several drugs in the benzimidazole family of chemicals, has cancer-fighting properties. This is especially true when paired with DCA, which is often reported by patients to cure their cancers. Earlier this year, we published an article that highlighted a man who claims to have eradicated his stage 4 pancreatic cancer using fenbendazole and DCA. Since then, more people have come forward claiming that this treatment helped them as well. These new reports merely delve deeper into the existing and mounting scientific evidence that demonstrates that fenbendazole may be an effective cancer treatment.
According to a recent report in Scientific Reports, fenbendazole has the potential to suppress the growth of tumor cells. It appears to do this by affecting the growth of microtubules. These are structures that provide structure to all cells. Researchers found that fenbendazole disrupted the proper formation of these microtubules in human cancer cells. The drug also impeded glucose uptake in cancer cells, effectively starving them.
It did this by inhibiting the expression of GLUT transporters. Insulin normally stimulates GLUT 4 to migrate across the microtubule to the plasma membrane where it can absorb sugar. However, fenbendazole blocked the movement of GLUT 4, thereby restricting insulin-stimulated glucose absorption and essentially starving cancer cells.
In addition to these effects, fenbendazole appeared to reduce the proliferation of tumor cells by altering multiple other cellular pathways. This may have been due to the fact that fenbendazole affects multiple cellular targets, as opposed to single-target drugs, which typically have limited efficacy and can lead to resistance.
The research team then tested fenbendazole on colorectal cancer cells in mice. The animals were given fenbendazole either in their diet or via three daily i.p. injections for 12 days. They then rigorously compared the time it took for tumors to grow from their initial volume to four times that volume. They also measured the number of tumors that were present and their size.
While the anecdotal evidence presented in this study is encouraging, the researchers point out that there isn’t sufficient proof that fenbendazole can act as a treatment for humans. For this, a randomized clinical trial would need to be conducted. Currently, fenbendazole is used as an antihelmintic in dogs to treat parasitic diseases and worms. It is also available as a generic medication for human use and has been shown to be well tolerated by people with no significant side effects. Therefore, it is possible that fenbendazole could play an important role in the future of cancer treatment. fenbendazole for humans
ashdev